Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus
Amer M. Zeidan(Yale Cancer Center), Matteo Della Porta(University of Milan), Jose Alberto Nadal(Bristol-Myers Squibb (Switzerland)), Krzysztof Mądry(Medical University of Warsaw), Rena Buckstein(Sunnybrook Health Science Centre), Lea Sahagun(Bristol-Myers Squibb (Sweden)), Ali McBride(University of Arizona), Dries Deeren(Inagro (Belgium)), José Miguel Torregrosa Diaz(Hospital General Universitario Morales Meseguer), Gitanjali Das(Bristol-Myers Squibb (Sweden)), Sebastian Grosicki(Medical University of Silesia), Yinzhi Lai(Bristol-Myers Squibb (United States)), Uwe Platzbecker(National Center for Tumor Diseases), Dimana Miteva(Bristol-Myers Squibb (Switzerland)), Valeria Santini(Azienda Ospedaliero-Universitaria Careggi), Lionel Adès(Centre National de la Recherche Scientifique), María Diez‐Campelo(Universidad de Salamanca), Sangeetha Venugopal(University of Miami), Tatiana Zelinsky(Bristol-Myers Squibb (Sweden)), David Valcárcel(Vall d'Hebron Hospital Universitari)
Cited by 1
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
|Journal of Clinical Oncology|2009|963